Libtayo®(cemiplimab)联合化疗的五年临床数据进一步证实,该治疗方案为晚期非小细胞肺癌患者带来了显著且持久的生存获益改善。
Libtayo®(cemiplimab)联合化疗的五年临床数据进一步证实,该治疗方案为晚期非小细胞肺癌患者带来了显著且持久的生存获益改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.